New applications of squalene synthase inhibitors: Membrane cholesterol as a therapeutic target
- 18 June 2020
- journal article
- review article
- Published by Wiley in Archiv der Pharmazie
- Vol. 353 (9) , e2000085
Abstract
Squalene synthase (SQS) inhibitors, mostly known as antihyperlipidemic agents for controlling blood cholesterol levels, have been increasingly used to study alterations of the cholesterol content in cell membranes. As such, SQS inhibitors have been demonstrated to control cellular activities related to cancer cell proliferation and migration, neuron degeneration, and parasite growth. While the mechanisms behind the effects of cellular cholesterol are still being revealed in detail, the evidence for SQS as a therapeutic target for several seemingly unrelated diseases is increasing. SQS inhibitors may be the next promising candidates targeting the three remaining primary therapeutic areas, beyond cardiovascular disease, which still need to be addressed; their application as anticancer, antimicrobial, and antineurodegenerative agents appears promising for new drug discovery projects underway.Keywords
This publication has 79 references indexed in Scilit:
- The Role of Lipid Rafts in Cancer Cell Adhesion and MigrationInternational Journal of Cell Biology, 2011
- STED Nanoscopy Reveals Molecular Details of Cholesterol- and Cytoskeleton-Modulated Lipid Interactions in Living CellsBiophysical Journal, 2011
- A Cholesterol Biosynthesis Inhibitor Blocks Staphylococcus aureus VirulenceScience, 2008
- Squalestatin alters the intracellular trafficking of a neurotoxic prion peptideBMC Neuroscience, 2007
- Quinuclidine Derivatives as Potential AntiparasiticsAntimicrobial Agents and Chemotherapy, 2007
- Squalestatin protects neurons and reduces the activation of cytoplasmic phospholipase A2 by Aβ1–42Neuropharmacology, 2007
- cDNA Microarray Analysis of Host-Pathogen Interactions in a Porcine In Vitro Model forToxoplasma gondiiInfectionInfection and Immunity, 2006
- Protein Sensors for Membrane SterolsCell, 2006
- Follow-up study of patients randomized in the scandinavian simvastatin survival study (4S) of cholesterol loweringThe American Journal of Cardiology, 2000
- Increased proximal tubular cholesterol content: Implications for cell injury and “acquired cytoresistance”Kidney International, 1999